The features of male breast cancer in China: A real-world study

Background: Male breast cancer (MBC) is a rare disease. Although several large-scale studies have investigated MBC patients in other countries, the features of MBC patients in China have not been fully explored. This study aims to explore the features of Chinese MBC patients comprehensively. Methods: We retrospectively collected data of MBC patients from 36 centers in China. Overall survival (OS) was evaluated by the Kaplan -Meier method, log -rank test, and Cox regression analyses. Multivariate Cox analyses were used to identify independent prognostic factors of the patients. Results: In total, 1119 patients were included. The mean age at diagnosis was 60.9 years, and a significant extension over time was observed ( P < 0.001). The majority of the patients (89.1 %) received mastectomy. Sentinel lymph node biopsy was performed in 7.8 % of the patients diagnosed in 2009 or earlier, and this percentage increased significantly to 38.8 % in 2020 or later ( P < 0.001). The five-year OS rate for the population was 85.5 % [95 % confidence interval (CI), 82.8 % -88.4 %]. Multivariate Cox analysis identified taxane-based [T -based, hazard ratio (HR) = 0.32, 95 % CI, 0.13 to 0.78, P = 0.012] and anthracycline plus taxane-based (A + T -based, HR = 0.47, 95 % CI, 0.23 to 0.96, P = 0.037) regimens as independent protective factors for OS. However, the anthracycline-based regimen showed no significance in outcome ( P = 0.175). Conclusion: As the most extensive MBC study in China, we described the characteristics, treatment and prognosis of Chinese MBC population comprehensively. T -based and A +T -based regimens were protective factors for OS in these patients. More research is required for this population.